Cooley M&A

JANUARY 22, 2020

2019 was a banner year for billion-dollar life sciences M&A transactions. A wave of big-ticket transactions by global pharmaceutical companies drove life sciences M&A activity to its fourth-largest year on record in 2019, with aggregate deal value in the pharmaceutical, medical and biotech industry reaching $234.2

M&A 40

M&A Pharmaceutical Acquisitions Capital 40

Cooley M&A

JANUARY 22, 2021

Although global deal value was a subdued $966 billion in the first half of 2020 (down nearly 50% compared to the first half of 2019), momentum skyrocketed in the second half of the year to nearly $2.2 compared to 2019. compared to 2019, and up even higher (57%) when looking solely at US deal value. COVID-19: The New Normal.

M&A 40

M&A IPO Mergers and Acquisitions Business 40

Cooley M&A

OCTOBER 29, 2020

On September 24, Cooley M&A partner, Garth Osterman, moderated a webinar on the current trend in going public: SPACs! As illustrated in Chart 2 above, the average amount of the PIPE raised in connection with the de-SPAC transaction has increased by more than 50%, from $185 million in 2019 to $282 million in YTD 2020. Larger PIPEs.

M&A 52

M&A IPO Valuation Mergers and Acquisitions 52

Cooley M&A

JANUARY 20, 2022

19 treatments from Pfizer, Merck and potentially others hitting the market soon , we expect Big Pharma to continue to parlay this cash flow into growth in other areas of strategic focus. on transactions over 2019’s mega?mergers. These players have looked further afield to add new capabilities and pipeline assets. closing friction.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40